InsidersTradesSigma
Explore the complete record of transactions filed by Kirkpatrick Lynn, Chief Executive Officer. Director active across 1 companies, notably Ensysce Biosciences, Inc.. Cumulatively, 3 disclosures have been recorded. Total volume traded: €32k. The latest transaction was disclosed on 25 May 2022 — Acquisition. Regulator: SEC (Form 4). The full history is free.
3 of 3 declarations
Lynn Kirkpatrick is the CEO of Ensysce Biosciences, Inc. In this role, he is responsible for the overall management of the company and the implementation of its strategy. Ensysce Biosciences, Inc. is a biopharmaceutical company. Lynn leverages his expertise to lead the company towards sustainable growth and strengthen its market position.